rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Oncolytics Biotech Inc.

ONCY · Nasdaq

Health CareBiotechnologyNot moving yet

ONCY stood above a rising 150-day average in 10 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 41.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$726K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
73 (+19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$470KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months14
Sale orders, 12 months0
Buyers · sellers10 · 0
WhoDidSharesTraded
Jared KellyChief Executive Officerbought5,050at $0.9612 Mar 2026filed 13 Mar 2026
James T. ParsonsDirectorbought10,000at $1.0311 Mar 2026filed 13 Mar 2026
Patricia S. AndrewsDirectorbought35,400at $0.855712 Feb 2026filed 13 Feb 2026
Deborah Margaret BrownDirectorbought25,000at $0.849612 Feb 2026filed 13 Feb 2026
Allison HagermanVP, Product Developmentbought10,000at $0.829812 Feb 2026filed 13 Feb 2026
Thomas Charles HeinemanChief Medical Officerbought12,132at $0.82712 Feb 2026filed 13 Feb 2026
Jared KellyChief Executive Officerbought29,500at $0.84212 Feb 2026filed 13 Feb 2026
Kirk LookChief Financial Officerbought12,000at $0.84212 Feb 2026filed 13 Feb 2026
Wayne PisanoDirectorbought30,000at $0.844612 Feb 2026filed 13 Feb 2026
Bernd R. SeizingerDirectorbought40,000at $0.846612 Feb 2026filed 13 Feb 2026
Andrew AromandoChief Business Officerbought29,600at $0.858711 Feb 2026filed 13 Feb 2026
Jared KellyChief Executive Officerbought5,600at $0.83611 Feb 2026filed 13 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders73+19 on the quarter
New · exited28 · 9
Reported value$3.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MARSHALL WACE, LLPreduced · filed 13 Aug 2026745,350$708K-114,481−13.3%
XTX Topco Ltdadded · filed 14 Aug 2026260,903$248K+151,145+137.7%
SEEDS INVESTOR LLCunchanged · filed 12 Aug 2026258,306$245K00.0%
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLCnew · filed 22 Jul 2026201,260$181K+201,260
Connective Capital Management, LLCnew · filed 13 Aug 2026185,712$176K+185,712
GOLDMAN SACHS GROUP INCnew · filed 14 Aug 2026169,898$161K+169,898
TOCQUEVILLE ASSET MANAGEMENT L.P.reduced · filed 10 Aug 2026147,000$140K-2,000−1.3%
Everhart Financial Group, Inc.added · filed 9 Jul 2026140,899$134K+2,738+2.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 2026134,129$127K+92,806+224.6%
PFG Investments, LLCadded · filed 23 Jul 2026128,300$122K+75,400+142.5%
31 Mar 2023 – 30 Jun 2026
295071Mar 23Dec 23Dec 24Sep 25Jun 26

News

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Paymentmanilatimes.net · 14 Oct 2026Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Updatenugget.ca · 12 Oct 2026Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Updatesimcoereformer.ca · 12 Oct 2026Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Updateintelligencer.ca · 12 Oct 2026Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Updatebrantfordexpositor.ca · 12 Oct 2026Baystreet.ca - Oncolytics Biotech Incbaystreet.ca · 28 Sep 2026Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Studymanilatimes.net · 28 Sep 2026Oncolytics Biotech Reports Encouraging Pelareorep Data In Colorectal Cancerrttnews.com · 10 Sep 2026

Everyone who traded it

Allison Hagerman Company insiderChief Technology Officer · last 1 Jun 20261 · 0
Andrew Aromando Company insiderChief Business Officer · last 1 Jun 20261 · 0
Angela Holtham Company insiderDirector · last 1 Jun 20260 · 0
Bernd R. Seizinger Company insiderDirector · last 1 Jun 20263 · 0
Deborah Margaret Brown Company insiderDirector · last 1 Jun 20261 · 0
James T. Parsons Company insiderDirector · last 1 Jun 20261 · 0
Jared Kelly Company insiderChief Executive Officer · last 1 Jun 20263 · 0
John Bearden McAdory Company insiderChief Operating Officer · last 1 Jun 20260 · 0
Jonathan Rigby Company insiderDirector · last 1 Jun 20260 · 0
Kirk Look Company insiderChief Financial Officer · last 1 Jun 20261 · 0
Patricia S. Andrews Company insiderDirector · last 1 Jun 20261 · 0
Stephen C. Glover Company insiderDirector · last 1 Jun 20260 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 23 Mar 20267.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.2M
Free cash flowFY 2025 · to 31 Dec 2025−$20.1M

Analyst forecasts

No analyst forecasts yet.